<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Viswanathan VS</submitter><funding>NCATS NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>Howard Hughes Medical Institute</funding><funding>NCI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>453-457</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5667900</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>547(7664)</volume><pubmed_abstract>Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness. A high-mesenchymal cell state observed in human tumours and cancer cell lines has been associated with resistance to multiple treatment modalities across diverse cancer lineages, but the mechanistic underpinning for this state has remained incompletely understood. Here we molecularly characterize this therapy-resistant high-mesenchymal cell state in human cancer cell lines and organoids and show that it depends on a druggable lipid-peroxidase pathway that protects against ferroptosis, a non-apoptotic form of cell death induced by the build-up of toxic lipid peroxides. We show that this cell state is characterized by activity of enzymes that promo</pubmed_abstract><journal>Nature</journal><pubmed_title>Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.</pubmed_title><pmcid>PMC5667900</pmcid><funding_grant_id>R01 GM085081</funding_grant_id><funding_grant_id>UL1 TR001102</funding_grant_id><funding_grant_id>P30 CA008748</funding_grant_id><funding_grant_id>R01 CA097061</funding_grant_id><funding_grant_id>U01 CA168397</funding_grant_id><funding_grant_id>K08 CA218420</funding_grant_id><funding_grant_id>R35 CA209896</funding_grant_id><funding_grant_id>R01 CA121941</funding_grant_id><funding_grant_id>R01 CA129933</funding_grant_id><funding_grant_id>R01 CA154480</funding_grant_id><funding_grant_id>U24 CA194107</funding_grant_id><funding_grant_id>U01 CA176058</funding_grant_id><funding_grant_id>U01 CA217848</funding_grant_id><funding_grant_id>R01 GM038627</funding_grant_id><funding_grant_id>P50 CA092629</funding_grant_id><funding_grant_id>R01 GM074024</funding_grant_id><funding_grant_id>R01 CA208100</funding_grant_id><funding_grant_id>R01 CA161061</funding_grant_id><funding_grant_id>P30 DK043351</funding_grant_id><funding_grant_id>R01 CA193837</funding_grant_id><funding_grant_id>U01 CA176152</funding_grant_id><funding_grant_id>U01 CA199253</funding_grant_id><pubmed_authors>Kaffenberger SD</pubmed_authors><pubmed_authors>Viswanathan VS</pubmed_authors><pubmed_authors>Huang C</pubmed_authors><pubmed_authors>Eaton JK</pubmed_authors><pubmed_authors>Stockwell BR</pubmed_authors><pubmed_authors>Rees MG</pubmed_authors><pubmed_authors>Haber DA</pubmed_authors><pubmed_authors>Tamayo P</pubmed_authors><pubmed_authors>Shamji AF</pubmed_authors><pubmed_authors>Dhruv HD</pubmed_authors><pubmed_authors>Boehm JS</pubmed_authors><pubmed_authors>Shimada K</pubmed_authors><pubmed_authors>Gao D</pubmed_authors><pubmed_authors>Seashore-Ludlow B</pubmed_authors><pubmed_authors>Levesque MP</pubmed_authors><pubmed_authors>Gill S</pubmed_authors><pubmed_authors>Chattopadhyay S</pubmed_authors><pubmed_authors>Boskovic ZV</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Viswanathan SR</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Aguirre AJ</pubmed_authors><pubmed_authors>Engelman JA</pubmed_authors><pubmed_authors>Wu X</pubmed_authors><pubmed_authors>Hahn WC</pubmed_authors><pubmed_authors>Hon CS</pubmed_authors><pubmed_authors>Berens ME</pubmed_authors><pubmed_authors>Javaid S</pubmed_authors><pubmed_authors>Tseng YY</pubmed_authors><pubmed_authors>Roider EM</pubmed_authors><pubmed_authors>Kotz JD</pubmed_authors><pubmed_authors>Ryan MJ</pubmed_authors><pubmed_authors>Clemons PA</pubmed_authors><pubmed_authors>Wolpin BM</pubmed_authors><pubmed_authors>Schreiber SL</pubmed_authors><pubmed_authors>Yang WS</pubmed_authors><pubmed_authors>Cleary JM</pubmed_authors><pubmed_authors>Doench JG</pubmed_authors><pubmed_authors>Eichhoff OM</pubmed_authors><pubmed_authors>Mesirov JP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.</name><description>Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness. A high-mesenchymal cell state observed in human tumours and cancer cell lines has been associated with resistance to multiple treatment modalities across diverse cancer lineages, but the mechanistic underpinning for this state has remained incompletely understood. Here we molecularly characterize this therapy-resistant high-mesenchymal cell state in human cancer cell lines and organoids and show that it depends on a druggable lipid-peroxidase pathway that protects against ferroptosis, a non-apoptotic form of cell death induced by the build-up of toxic lipid peroxides. We show that this cell state is characterized by activity of enzymes that promo</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Jul</publication><modification>2026-04-16T07:15:46.86Z</modification><creation>2019-03-26T23:47:50Z</creation></dates><accession>S-EPMC5667900</accession><cross_references><pubmed>28678785</pubmed><doi>10.1038/nature23007</doi></cross_references></HashMap>